Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationDepreciation & Amortization (IS)EBIATLeasesLong-Term Debt IssuancesOther Gross PP&E AdjustmentsPreferred Shares IssuedProperty, Plant & Equipment (Gross)Shares IssuedShares OutstandingShort-Term Debt issuancesWages, Salaries and Other
Ratios

Coeptis Therapeutics Holdings (COEP) EBIAT (2021 - 2025)

Historic EBIAT for Coeptis Therapeutics Holdings (COEP) over the last 5 years, with Q3 2025 value amounting to -$2.9 million.

  • Coeptis Therapeutics Holdings' EBIAT fell 5849.64% to -$2.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$12.2 million, marking a year-over-year decrease of 19677.66%. This contributed to the annual value of -$9.8 million for FY2024, which is N/A changed from last year.
  • As of Q3 2025, Coeptis Therapeutics Holdings' EBIAT stood at -$2.9 million, which was down 5849.64% from -$4.3 million recorded in Q2 2025.
  • In the past 5 years, Coeptis Therapeutics Holdings' EBIAT registered a high of $17.5 million during Q4 2023, and its lowest value of -$19.2 million during Q1 2022.
  • Over the past 5 years, Coeptis Therapeutics Holdings' median EBIAT value was -$3.1 million (recorded in 2025), while the average stood at -$2.7 million.
  • Per our database at Business Quant, Coeptis Therapeutics Holdings' EBIAT plummeted by 23628.86% in 2022 and then skyrocketed by 69500.78% in 2023.
  • Over the past 5 years, Coeptis Therapeutics Holdings' EBIAT (Quarter) stood at $14.1 million in 2021, then crashed by 120.91% to -$2.9 million in 2022, then soared by 695.01% to $17.5 million in 2023, then plummeted by 111.12% to -$1.9 million in 2024, then tumbled by 48.81% to -$2.9 million in 2025.
  • Its last three reported values are -$2.9 million in Q3 2025, -$4.3 million for Q2 2025, and -$3.1 million during Q1 2025.